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The synthetic atria1 peptides, rat atria1 natriuretic peptide, atriopeptin I and atriopeptin II, stimulated testos- 
terone production by mouse Leydig cells in a time- and concentration-dependent manner. The maximum 
stimulation of the steroidogenesis n response to the peptides was 6lo-fold over the basal level, as compared 
with 20-24-fold stimulation obtained with saturating concentrations of hCG. The stimulation of steroido- 
genesis by the most potent peptide, atriopeptin II, was markedly enhanced in the presence of the phosphodi- 
esterase inhibitor, 3-isobutyl-I-methylxanthine, suggesting an involvement of cyclic nucleotides. However, 
neither basal nor hCG-stimulated levels of CAMP were altered by the peptide, though testosterone produc- 
tion in response to submaximal concentrations of hCG was increased in the presence of atriopeptin II. The 
nature of the second messenger involved and the mechanism of action of the atria1 peptides may by elucidat- 
ed by further research in progress. 
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1. INTRODUCTION 
In 1981, De Bold et al. [l] reported that the in- 
jection of rat atria1 muscle extract into rats pro- 
duced a marked diuresis, natriuresis and hypoten- 
sion. Since then, several forms of the polypeptide, 
atrial natriuretic factor (ANF) have been isolated 
and identified [2-61. The molecular mechanism of 
action of ANF remains unclear. However, on the 
basis of the reported data [7-IO], it has been sug- 
gested that the effects of ANF are mediated 
through cyclic GMP (cGMP). Waldman et al. [9] 
showed that the guanylate cyclase activity in a 
membrane preparation from kidney was rapidly 
stimulated by ANF and that the phenomenon of 
guanylate cyclase activation by ANF was not 
restricted to kidney alone but was also observed in 
other tissues such as aorta, lung, intestine and 
testis. This observation implied that ANF may be 
involved in the regulation of cellular functions in 
diverse tissues. Indeed, ANF has recently been 
shown to inhibit steroidogenesis n adrenocortical 
cells (1 l-l.51 and murine tumour Leydig cells 1161. 
Atarashi et al. 11 l] reported that the crude extract 
of rat atria could inhibit both basal as well as 
ACTH- and angiotensin II-stimulated aldosterone 
production by rat zona glomerulosa cells. Similar 
observations have been reported by other authors 
112-151 using synthetic ANF. The suppression of 
steroidogenesis has been attributed to the ability of 
ANF to stimulate cGMP formation 1151. In murine 
tumour Leydig cells synthetic ANF inhibited both 
basal and gonadotrophin-stimulated progesterone 
production, accompanied by a marked inhibition 
of cyclic AMP (CAMP) formation and stimulation 
of cGMP accumulation [16]. These observations 
on the effect of ANF on steroidogenesis prompted 
us to investigate whether testosterone production 
by purified mouse Leydig cells could be modulated 
by ANF. Here three different forms of ANF have 
been used, which are as follows: (a) rat atria1 
natriuretic peptide (rANP), (b) atriopeptin I (rAP- 
I) and (c) atriopeptin II (rAP-II). 
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2. MATERIALS AND METHODS 
The following synthetic peptides were obtained 
from Serva, Heidelberg: rANP(l-28) [2], rAP- 
I(5-25) [4] and rAP-II(Phe-22,Arg-23) [4]. Highly 
purified human chorionic gonadotrophin (hCG, 
13 500 IU/mg) was from Boehringer, Mannheim. 
The sources of other chemicals used were as 
follows: bovine serum albumin from Sigma, 
Munich; 3-isobutyl-1-methylxanthine (IBMX) 
from Aldrich-Europe, Beerse, Belgium; minimum 
essential medium with Earle’s salts from Gibco 
Europe, Karlsruhe; Hepes from Serva, Heidelberg. 
Preparation and purification of Leydig cells 
from the testes of adult NMRI mice have been 
described [ 17,181. In general, percoll-purified 
Leydig cells (50000-100000 cells) were incubated 
in 500~1 minimum essential medium containing 
25 mM Hepes, pH 7.4, and 0.1% bovine serum 
albumin (medium) for 3 h or as indicated at 36”C, 
with or without various test substances. All pep- 
tides were dissolved in 10 mM sodium phosphate 
buffer, pH 7.0, containing 0.15 mM NaCl and 
0.1% bovine serum albumin, at a concentration of 
low4 M. This stock solution was appropriately 
diluted with medium prior to the addition to the in- 
cubation medium. 
Testosterone produced in the medium was 
assayed by a radioimmunoassay as described in 
[17,18]. For the determination of CAMP, the in- 
cubation was stopped by the addition of 2.0 ml 
cold absolute ethanol followed by vortex-mixing. 
The ethanol extract was evaporated to dryness, the 
residue was dissolved in 200-500 ,J of 0.1% 
sodium azide and the content of CAMP was 
measured by a specific radioimmunoassay [ 17,181. 
Each experiment was performed at least twice. 
The results presented are mean + SD of triplicate 
or quadruplicate determinations, as indicated in 
the legends to the figures. 
3. RESULTS 
The results presented in fig.1 show that a dose- 
related stimulation of testosterone production (A) 
occurred following incubation of mouse Leydig 
cells with varying concentrations of rAP-II, rAP-I 
and rANP. The amount of testosterone produced 
by these cells in the presence of maximal 
steroidogenic oncentration of hCG (2 ng/ml) was 
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Fig. 1. (A) Dose response of testosterone production by 
ANF in mouse Leydig cells. Percoll-purified mouse 
Leydig cells were incubated at 36°C for 3 h in the 
presence of varying concentrations of either rANP (A). 
rAP-I (0) or rAP-II (0) and the amount of testosterone 
produced was measured by radioimmunoassay as 
mentioned in section 2. The data represent means + SD 
of triplicate determinations. The vertical bars show the 
SD and have been omitted where they were smaller than 
the symbols. (B) Time course of stimulation of 
steroidogenesis in response to ANF. The cells were 
incubated in the absence of any addition (0) or in the 
presence of 1 x lo-’ M rANP (0), 1 x lo-’ M rAP-I 
(A) or 1 X 10-s M rAP-II (0) for varying periods of 
time and testosterone produced was measured. The 
results are the means of three determinations. The SD in 
each case was less than 10% of the mean value and is not 
shown for the sake of clarity. 
91.4 f 9.0 ng/lO’ cells per 3 h. Thus, the max- 
imum stimulation of steroidogenesis achieved with 
the peptides was about 40% of that obtained with 
2 ng/ml hCG and was comparable to the level of 
steroidogenesis obtained with 0.1 ng/ml hCG. The 
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cells incubated with 0.1 ng/ml hCG produced 43.0 
f 4.6 ng testosterone/lo5 cells per 3 h. The max- 
imal effective concentrations of rAP-II, rANP and 
rAP-I were lo-‘, 2 x lo-’ and 2 x lo-’ M, respec- 
tively. At higher concentrations of both rAP-11 
and rANP, a decline in steroidogenesis was noted. 
In an experiment where higher concentrations of 
rAP-I were used, a decline in the extent of stimula- 
tion of testosterone production was observed at 
concentrations of rAP-I beyond 5 x IO-’ M (not 
shown). 
Half-maximum stimulation of steroidogenesis 
was achieved with 2.6 x 10e9 M rAP-II, 8.0 x 
10T9 M rANP and 3.8 x lo-’ M rAP-I. The extent 
of maximum stimulation of steroidogenesis by 
each of the peptides varied somewhat between ex- 
periments using different batches of the cell 
preparations. In 6 separate experiments, the 
amounts of testosterone produced in the presence 
of maximal steroidogenic concentrations of the 
peptides varied between 6- and lo-times that pro- 
duced in the absence of the peptides. 
Fig.lB shows the time course of stimulation of 
testosterone production by Leydig cells in the 
presence of rAP-II (1 x lo-’ M), rAP-I (1 x 
lo-’ M) and rANP (1 x lo-’ M). It is evident that 
each of the three peptides caused a time-related in- 
crease in the amount of testosterone produced, and 
a significant difference between the stimulated and 
basal levels of steroidogenesis was observed as ear- 
ly as 1 h from the start of the incubation. Having 
shown that all three peptides can stimulate 
steroidogenesis, further experiments were carried 
out with the most potent one, rAP-II. 
In the presence of a phosphodiesterase inhibitor, 
IBMX (0.25 mM), rAP-II-induced testosterone 
production by Leydig cells was markedly enhanced 
(fig.2). The concentration of rAP-II required to 
elicit a half-maximal steroidogenic response was 
reduced from 3.0 x 10e9 M in the absence of 
IBMX to 6.0 x lo-” M in the presence of IBMX. 
There was little effect of IBMX on basal 
steroidogenesis. Low concentrations of rAP-II (2 
x lo-” and 5 x lo-” M), which did not stimulate 
testosterone production at all in the absence of 
IBMX, effected an enhanced steroidogenic 
response when IBMX was present. 
The effect of rAP-II on hCG-induced 
testosterone production by mouse Leydig cells is 
shown in fig.3. The basal level of testosterone pro- 
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Fig.2. Effect of the phosphodiesterase inhibitor, IBMX, 
on the testosterone production by mouse Leydig cells in 
response to varying concentrations of rAP-II. The 
Leydig cells were incubated with varying concentrations 
of rAP-II in the absence (0) or presence (0) of 
0.25 mM IBMX and the amount of testosterone 
produced was measured. Other details are the same as in 
the legend to fig. 1. 
0 0.02 0.05 0.1 0.2 0.5 1.0 
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Fig.3. Effect of rAP-II on the dose-response curve of 
hCG. Mouse Leydig cells were incubated with varying 
concentrations of hCG in the absence (0) or presence 
(0) of 1 x 10M8 M rAP-II and testosterone produced 
was measured. Other details are the same as in the legend 
to fig. 1. 
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duction was increased lo-fold by rAP-II. In the 
presence of rAP-II, low concentrations of hCG 
(0.02-0.1 ng/ml) produced increased amounts of 
testosterone. However, the differences in the 
amounts of the steroid produced in the presence or 
absence of rAP-II decreased gradually with in- 
creasing doses of hCG. At saturating concentra- 
tions of hCG, no effect of rAP-II was seen. Since 
it has been reported that only low concentrations 
of ANF (1 x 10e9 M) produced a strong inhibition 
of hCG and LH-stimulated progesterone produc- 
tion by mouse tumour Leydig cells and that higher 
concentrations of ANF (1 x 10-‘-l x 10e6 M) 
were ineffective 1161, we have examined the effect 
of addition of varying concentrations of rAP-II 
(10-‘“-10-6 M) on testosterone production by 
mouse Leydig cells stimulated with a submaximal 
concentration of hCG (0.2 ng/ml). No inhibitory 
effect was observed at any concentration of rAP-II 
(not shown). 
Fig.4 shows the effect of rAP-II on hCG- 
induced CAMP responses in mouse Leydig cells. In 
Fig.4. Effect of rAP-II on the hCG-stimulated CAMP 
response in mouse Leydig cells. The Leydig cells were 
incubated for 20 min in the presence of 0.25 mM IBMX 
with the following additions: (1) none; (2) 0.2 ng/ml 
hCG; (3) 2 ng/ml hCG; (4) 20 ng/ml hCG; (5) 2 ng/ml 
hCG plus 5 x 10m9 M rAP-II; (6) 2 ng/ml hCG plus 1 x 
10-s M rAP-II and (7) 2 ng/ml hCG plus 2 x IO-’ M 
rAP-II. CAMP produced was assayed as described in 
section 2. The data are means ? SD of quadruplicate 
determinations. 
the presence of increasing concentrations of hCG, 
the amount of CAMP accumulated increased in a 
dose-related manner. The addition of increasing 
concentrations of rAP-II in the presence of 
2 ng/ml hCG had no effect on the amount of 
CAMP accumulated. In a separate xperiment, the 
effect of varying concentrations of rAP-II 
(10-9-10-6 M) on the CAMP accumulation by the 
cells in the absence of hCG was examined and no 
increase in the basal level of CAMP was effected by 
rAP-II (Mukhopadhyay, unpublished). 
4. DISCUSSION 
The results obtained demonstrate that ANF can 
stimulate steroidogenesis by percoll-purified 
mouse Leydig cells in a time- and dose-related 
manner. Among the peptides used, rAP-II was the 
most potent one and the least active peptide was 
rAP-I. In terms of natriuretic potency, rAP-I has 
been reported to be 4-times less potent than rAP-II 
[4]. In mouse Leydig cells, the steroidogenic poten- 
cy of rAP-II was 15times greater than rAP-I. The 
amino acid composition of rAP-I is identical to 
that of rAP-II except for the presence of Phe-Arg 
extension at the carboxy-terminal of rAP-II. The 
carboxy-terminal amino acids, therefore, appear 
to be important determinants for steroidogenic ac- 
tivity. The longer peptide, rANP, differs from 
rAP-II in having an extended chain of Ser-Leu- 
Arg-Arg residues at the amino-terminal end and an 
additional Tyr residue at the carboxy-terminal end. 
Whether the lower steroidogenic potency of rANP 
compared to rAP-II results from the addition of 
extra amino acid residues at the amino-terminal or 
at the carboxy-terminal, cannot at present be 
clarified. Further studies with other synthetic ANF 
peptides having various chain lengths are necessary 
to identify the activity-determinant region. 
The stimulation of basal steroidogenesis by rAP- 
II was strongly potentiated by a phosphodiesterase 
inhibitor, IBMX, indicating therefore, that a cyclic 
nucleotide is involved in mediating the effect of 
rAP-II in mouse Leydig cells. However, neither 
basal nor hCG-stimulated levels of CAMP were in- 
creased by rAP-II, though in addition to 
stimulating the steroidogenesis in the absence of 
hCG, rAP-II also increased the amount of 
testosterone produced in response to submaximal 
hCG concentrations. Thus a role for CAMP ap- 
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pears to be unlikely. Of course, the possibility that 
rAP-II might have caused a small but undetectable 
increase in CAMP level that was sufficient to effect 
a stimulation of steroidogenesis, cannot be exclud- 
ed yet. Alternatively, a rAP-II-induced shift from 
free to bound levels of CAMP might also be 
responsible for the stimulation of steroidogenesis. 
A role for cGMP has been indicated in mediating 
the effects of ANF in a variety of tissues 
[8-10,15,16]. The possibility remains that in 
mouse Leydig cells also, cGMP may be the second 
messenger involved. Available data do not offer as 
yet a choice between these possibilities and further 
studies are in progress to determine the nature of 
the second messenger. 
We do not yet understand the reason for the 
discrepancy between the present result and that 
reported recently in murine tumour Leydig cells 
[1619 where ANF markedly inhibited both 
steroidogenesis as well as CAMP accumulation. 
Possibly the action of ANF is specific to the type 
of target tissue under investigation. Indeed, the 
neurohypophysial peptide, GnRH, has been shown 
to stimulate steroidogenesis n rat Leydig cells [ 191 
while in rat luteal cells progesterone production 
was inhibited by GnRH [20]. In an analogous man- 
ner, it may not be surprising if ANF produces op- 
posite effects in different tissues. 
The evidence on the effect of ANF on CAMP ac- 
cumulation is rather equivocal. No effect of ANF 
on CAMP level was observed in single nephron 
segments and glomeruli [21], or in arterial plasma 
following infusion of ANF into canine renal artery 
[22] or in isolated rabbit aortic segments [8]. On 
the other hand, in murine tumour Leydig cells [16] 
and in the rat pituitary [23], a marked inhibitory 
effect of ANF on CAMP formation has been 
reported. The latter report was contradicted by 
Heisler et al. [24] who did not observe any effect 
of ANF on adenylate cyclase activity in the rat 
pituitary homogenate. The results in the present 
study also exclude an inhibitory effect of ANF on 
CAMP levels in mouse Leydig cells. 
The physiological relevance of the observed ef- 
fects of ANF on mouse Leydig cells still remains a 
matter of speculation. Further studies are 
necessary to define the role of ANF in the regula- 
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